Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro-Reference-Cited by-同舟云学术

Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro

Published:2021-07 Issue: Volume:191 Page:105089
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Paull Jeremy R.A.^ORCID,Heery Graham P.^ORCID,Bobardt Michael D.,Castellarnau Alex,Luscombe Carolyn A.^ORCID,Fairley Jacinth K.^ORCID,Gallay Philippe A.

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference37 articles.

1. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and Guinea pig models of genital herpes;Bernstein;Antimicrob. Agents Chemother.,2003

2. Two phase 3, double-blinded, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis;Chavoustie;Eur. J. Obstet. Gynecol. Reprod. Biol.,2020

3. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis;Chen;J. Acquir. Immune Defic. Syndr.,2009

4. Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition;Connell;Front. Immunol.,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium;Scientific Reports;2024-09-11

2. Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial;Pharmaceutics;2024-09-06

3. Development of Nanomaterials as Drug Candidates;Nanotechnology in Drug Discovery;2024-07-04

4. Integration of Dendrimer‐Based Delivery Technologies with Computational Pharmaceutics and Their Potential in the Era of Nanomedicine;Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0;2024-06-21

5. Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases;Pharmaceutical Nanotechnology;2024-02